selonsertib

ASK1 inhibitor

Also Known As:

5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)-2-pyridinyl)-4-methylbenzamide; Benzamide, 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(4-(1-methylethyl)-4H-1,2,4-triazol-3-yl)-2-pyridinyl)-

Networked: 28 relevant articles (4 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Myers, Robert P: 11 articles (01/2022 - 01/2018)
2.	Goodman, Zachary: 8 articles (01/2022 - 10/2018)
3.	Lawitz, Eric J: 6 articles (01/2022 - 01/2019)
4.	Younossi, Zobair M: 6 articles (01/2022 - 10/2018)
5.	Loomba, Rohit: 6 articles (01/2022 - 01/2018)
6.	Alkhouri, Naim: 5 articles (01/2022 - 11/2019)
7.	Anstee, Quentin M: 5 articles (01/2022 - 11/2019)
8.	Harrison, Stephen A: 5 articles (01/2022 - 11/2019)
9.	Okanoue, Takeshi: 5 articles (01/2022 - 11/2019)
10.	Romero-Gomez, Manuel: 5 articles (01/2022 - 11/2019)

Related Diseases

1.	Liver Cirrhosis (Hepatic Cirrhosis) 11/01/2020 - "In this study, we investigated whether selonsertib, a selective inhibitor of ASK1, shows therapeutic efficacy for liver fibrosis, and elucidated its mechanism of action in vivo and in vitro. " 11/01/2020 - "Therefore, we suggest that selonsertib may be an effective therapeutic drug for ameliorating liver fibrosis." 11/01/2020 - "Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/ MAPK Pathway of Hepatic Stellate Cells." 01/01/2023 - "Liver fibrosis was staged centrally at baseline and week 48 (selonsertib study) or week 96 (simtuzumab study). " 11/01/2020 - "Interestingly, dimethylnitrosamine (DMN)-induced liver fibrosis was significantly alleviated by selonsertib treatment in rats. "
2.	Non-alcoholic Fatty Liver Disease 01/01/2018 - "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial." 01/01/2023 - "This study evaluated the performance of noninvasive tests among white and Asian patients in the STELLAR trials (NCT03053050 and NCT03053063), which evaluated selonsertib in patients with advanced (F3-F4) fibrosis due to nonalcoholic steatohepatitis (NASH). " 01/01/2018 - "Conclusion: These findings suggest that selonsertib may reduce liver fibrosis in patients with nonalcoholic steatohepatitis and stage 2-3 fibrosis. " 01/01/2018 - "We evaluated the safety and efficacy of selonsertib, a selective inhibitor of apoptosis signal-regulating kinase 1, alone or in combination with simtuzumab, in patients with nonalcoholic steatohepatitis and stage 2 or 3 liver fibrosis. "
3.	Neoplasms (Cancer) 01/01/2022 - "We concluded that targeting CDK6 by selonsertib can be an efficient therapeutic approach to cancer and other CDK6-related diseases. " 01/01/2019 - "Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells." 01/01/2019 - "This study provides a clue into a novel treatment strategy, which includes a combination of selonsertib with antineoplastic drugs to attenuate MDR-mediated by ABCB1 or ABCG2 in cancer cells overexpressing these transporters."
4.	Fibrosis (Cirrhosis) 01/01/2020 - "We conducted 2 randomized, double-blind, placebo-controlled, phase III trials of selonsertib in patients with NASH and bridging fibrosis (F3, STELLAR-3) or compensated cirrhosis (F4, STELLAR-4). " 11/01/2019 - "We analyzed screening data from two phase 3 trials of selonsertib to assess the ability of NITs to discriminate advanced fibrosis. " 11/01/2019 - "We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation. " 01/01/2019 - "We analyzed data from patients with NASH and stage 2 or 3 fibrosis enrolled in a phase II study of selonsertib. " 01/01/2020 - "We did not find that selonsertib reduced fibrosis in these patients. "
5.	Diabetic Nephropathies (Diabetic Nephropathy) 11/01/2019 - "Indeed, the ASK1 inhibitor Selonsertib has undergone clinical trials for diabetic kidney disease. " 10/01/2019 - "Although the trial did not meet its primary endpoint, exploratory post hoc analyses suggest that selonsertib may slow diabetic kidney disease progression." 10/01/2019 - "Effects of Selonsertib in Patients with Diabetic Kidney Disease." 10/01/2019 - "In a phase 2 trial evaluating selonsertib's safety and efficacy in adults with type 2 diabetes and treatment-refractory moderate-to-advanced diabetic kidney disease, we randomly assigned 333 adults in a 1:1:1:1 allocation to selonsertib (oral daily doses of 2, 6, or 18 mg) or placebo. " 12/01/2022 - "Selonsertib is a first-in-class apoptosis signal-regulating kinase 1 (ASK1) inhibitor in clinical trials for treating NASH and diabetic kidney disease due to its anti-inflammatory and anti-fibrotic activities. "

Related Drugs and Biologics

1.	simtuzumab
2.	cenicriviroc
3.	MAP Kinase Kinase Kinase 5
4.	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acid
5.	obeticholic acid
6.	Peroxisome Proliferator-Activated Receptors (PPAR)
7.	Chemokine Receptors
8.	3- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acid
9.	Antineoplastic Agents (Antineoplastics)
10.	lanifibranor

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)